Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Journal Volume
41
Journal Issue
31
Date Issued
2023-11-01
Author(s)
Goto, Koichi
Goto, Yasushi
Kubo, Toshio
Ninomiya, Kiichiro
Kim, Sang-We
Planchard, David
Ahn, Myung-Ju
Smit, Egbert F
de Langen, Adrianus Johannes
Pérol, Maurice
Pons-Tostivint, Elvire
Novello, Silvia
Hayashi, Hidetoshi
Shimizu, Junichi
Kim, Dong-Wan
Kuo, Chih-Hsi
Pereira, Kaline
Cheng, Fu-Chih
Taguchi, Ayumi
Cheng, Yingkai
Feng, Wenqin
Tsuchihashi, Zenta
Jänne, Pasi A
Abstract
Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd 5.4 mg/kg has not been evaluated in patients with previously treated human epidermal growth factor receptor 2-mutant (HER2m; defined as single-nucleotide variants and exon 20 insertions) metastatic non-small-cell lung cancer (mNSCLC).
SDGs
Type
journal article